指南与共识头颈与中枢神经肿瘤

CSCO与ASCO指南:II-IVA期鼻咽癌根治性放化疗联合化疗

Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2021-01-06

中国临床肿瘤学会(CSCO)与美国临床肿瘤学会(ASCO)联合召集专家小组,基于1990至2020年发表的系统综述、荟萃分析和随机对照试验,针对II-IVA期鼻咽癌根治性放化疗中的化疗联合问题制定循证推荐。文献检索共纳入108项相关研究,围绕五个总体临床问题(包括放疗、化疗顺序及同期、诱导和辅助化疗选择)形成推荐意见。

要点

  • 指南针对II-IVA期鼻咽癌根治性放化疗中的化疗联合策略给出循证推荐。
  • 证据基础来自1990至2020年的108项系统综述、荟萃分析和随机对照试验。
  • 推荐涵盖放疗、化疗顺序及同期、诱导和辅助化疗选项。

核心结论

  • CSCO与ASCO联合发布指南,为II-IVA期鼻咽癌根治性放化疗中的化疗联合提供循证推荐。

研究设计与样本

  • CSCO与ASCO召集放射肿瘤、肿瘤内科、外科及倡导代表组成的专家小组制定联合指南。
  • 文献检索涵盖1990年至2020年发表的系统综述、荟萃分析和随机对照试验,共纳入108项相关研究。
  • 专家小组基于证据和非正式共识形成循证指南推荐。

主要发现

  • 文献检索识别108项相关研究作为指南证据基础。
  • 指南涉及五个总体临床问题,包括放疗、化疗顺序及同期、诱导和辅助化疗选项的子问题。

关键数值与推荐

  • 推荐涉及II至IVA期鼻咽癌根治性放化疗中化疗联合的多个方面。

临床怎么用

  • 执业医师及其他医疗提供者可参考本指南对II-IVA期鼻咽癌患者进行根治性放化疗中的化疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this joint guideline is to provide evidence-based recommendations to practicing physicians and other healthcare providers on definitive-intent chemoradiotherapy for patients with stage II-IVA nasopharyngeal carcinoma (NPC). METHODS: The Chinese Society of Clinical Oncology (CSCO) and ASCO convened an expert panel of radiation oncology, medical oncology, surgery, and advocacy representatives. The literature search included systematic reviews, meta-analyses, and randomized controlled trials published from 1990 through 2020. Outcomes of interest included survival, distant and locoregional disease control, and quality of life. Expert panel members used this evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 108 relevant studies to inform the evidence base for this guideline. Five overarching clinical questions were addressed, which included subquestions on radiotherapy (RT), chemotherapy sequence, and concurrent, induction, and adjuvant chemotherapy options. RECOMMENDATIONS: Evidence-based recommendations were developed to address aspects of care related to chemotherapy in combination with RT for the definitive-intent treatment of stage II to IVA NPC.Additional information is available at www.asco.org/head-neck-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Chen YP, Ismaila N, Chua MLK, et al. Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO Guideline. J Clin Oncol. 2021. PMID: 33405943. doi:10.1200/JCO.20.03237

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。